When can a care home give a resident medicine covertly?

Stop the proposed hidden dose and define the problem

A resident has repeatedly refused a prescribed tablet. A relative suggests crushing it into pudding because the treatment is important. A worker wants to help, but hiding a medicine is a major decision about autonomy, consent and treatment. It is not a small change to the administration method. The home should not give a hidden dose while it works out the paperwork. It should protect the resident, record the refusal and ask the appropriate clinical team to assess the immediate treatment risk.

Covert administration means giving medicine without the person knowing, often by disguising it in food or drink. NICE SC1 says medicine must not be given covertly to a resident who has capacity to decide about that treatment. A person’s refusal may worry staff and family, but concern does not remove the person’s right to make a capacitous decision. A diagnosis of dementia or residence in a care home does not, by itself, establish incapacity for every medicine decision.

Ask why the medicine is being refused. The person may not understand what it is, may struggle to swallow, dislike a side effect, fear harm or simply choose not to take it. Offer accessible information and a calm explanation without coercion. Ask the prescriber or pharmacist whether the treatment is still needed, whether timing or formulation can be changed, or whether another lawful approach is available. A clinical review may remove the need for covert administration entirely.

The resident-refusal guide owns the immediate response to a stated “no.” This page starts when the multidisciplinary team is considering a formal plan to administer one or more medicines without the resident’s knowledge. It needs a different level of assessment, authorisation, technical advice and ongoing review. It must never be treated as an automatic next step after several refusals.

Assess capacity for each treatment decision

The Mental Capacity Act starts with a presumption of capacity. The person must receive support to decide, and an unwise decision does not itself prove incapacity. Capacity is specific to the decision at the time it needs to be made. A resident may understand one medicine and not another, or may have a temporary change in cognition during illness. The professional responsible for the decision should record what information the resident was given, how communication was supported and why there is a genuine reason to doubt capacity.

NICE SC1 says prescribing health professionals should assess capacity when there is concern about informed consent and record the assessment in the resident’s care record. It also says capacity should be reviewed at a frequency that reflects the cause of the incapacity, including whether it may fluctuate or be temporary. The provider should not rely on a single old global note saying “lacks capacity” for every medicine and every future dose.

The assessment must address the actual treatment choice. Can the person understand relevant information, retain it long enough, use or weigh it and communicate a decision? Give the information in an accessible way, use hearing or communication aids and allow a suitable time. A resident who refuses because they dislike a side effect may be making a considered choice. Staff should not use the capacity process to reverse a decision simply because others disagree with it.

If the person has capacity for the medicine decision, do not give it covertly. Record the refusal, provide support and seek clinical advice about the consequences and alternatives. If capacity is lacking for that decision, the team can consider the best-interests process. Lack of capacity opens a decision route; it does not make every proposed hidden administration lawful or necessary.

Make a medicine-specific best-interests decision

NICE SC1 recommends a best-interests meeting involving care-home staff, the prescribing health professional, a pharmacist and a family member or advocate. The team should consider the resident’s past and present wishes, feelings, beliefs and values. Include the person as far as possible. Ask what treatment benefit is expected, what harm may follow from omission, whether less restrictive alternatives exist and whether the proposed covert route is proportionate.

CQC’s covert-administration guidance says the need must be identified for each medicine prescribed. Do not approve “all regular medicines covertly” in one broad instruction. One treatment may be essential while another can be stopped or changed. The decision and method may differ between a tablet, liquid and inhaler. A medicine-specific record keeps the reasoning visible and prevents a new prescription from silently inheriting an old plan.

Consider the role of a person with legal authority to make health and welfare decisions, and whether advocacy is needed. A relative’s view is valuable evidence about the resident’s wishes, but being a relative does not by itself create authority to consent to covert treatment. The prescriber, pharmacist, care provider, attorney or advocate may have different roles. Clarify them before the decision. If people disagree or the treatment is particularly serious, seek specialist legal and clinical advice rather than asking a care worker to resolve the dispute on a medicines round.

Record the reasoning, not just a ticked box. What alternatives were tried? Why were they unsuitable? What does the resident appear to want? How would the proposed treatment benefit them? What burden or distress might it cause? When and by whom will the decision be reviewed? The record should allow a worker on a later shift to see that the plan was considered for this resident and this medicine, not copied from a template.

Resolve disagreement before a hidden administration

A relative may insist on covert dosing while the resident continues to object, or professionals may disagree about capacity and benefit. Pause the proposed hidden dose and make the disagreement visible to the prescriber and safeguarding lead. Clarify whether anyone has a valid health and welfare decision-making role and whether the medicine is urgent enough to need immediate clinical advice. Record each view fairly, including the resident’s words. If the team cannot reach a defensible decision, obtain specialist legal or ethics advice through the provider’s route. A family request, a staff vote or a manager’s signature alone does not settle the legal question. The care team still needs a plan for safe support while the dispute is resolved.

Get pharmaceutical advice on the actual method

Even a valid best-interests decision does not prove that a tablet can be crushed or mixed with a particular food. Some formulations must not be altered because the dose may be released differently, the medicine may not remain stable, the taste may reveal it or a partial meal may mean the person receives an uncertain amount. Ask a pharmacist for medicine-specific advice and document the exact method. Staff must not invent a method from internet snippets or assume all tablets can be treated alike.

The plan should identify the medicine, dose, timing, approved formulation, food or drink vehicle if used, preparation steps, administration method and what to do if the person does not consume the full amount. It should state who supplied the advice and when. If a medicine or formulation changes, pause and review the method before using the old instruction. A new brand, strength or dose may make the previous approach unsafe even when the medicine name looks familiar.

Consider the practical setting. Can the dose be prepared privately and given consistently by trained staff? Is the selected food compatible with the person’s allergies, swallowing plan or dietary preferences? Could the medicine be left unattended or given to someone else by mistake? If a resident shares meals, staff need a safe process that protects others without making the person’s routine conspicuously different. The pharmacist and prescriber should help resolve these details.

Record administration accurately on the medicines administration record and care record in line with the agreed process. The entry should not pretend the resident knowingly accepted the medicine. Workers who deliver the dose need access to the authorised plan and must be assessed as competent for their role. If they are unsure about preparation, a partial dose or a refusal of the disguised food, they should seek advice rather than improvising or marking the medicine as given.

Keep the resident’s experience and dignity in view

The person may not know a medicine is present, but they still experience the care interaction. Avoid threats, force or a routine that causes distress. Watch for signs that they dislike the chosen food, become suspicious or are upset by the process. Ask whether the plan can be less restrictive. A covert decision should not become permission to disregard the resident’s present behaviour and wellbeing.

Maintain opportunities for the person to make other choices. A decision that they lack capacity for one medicine does not remove their ability to choose a meal, express pain, consent to another treatment or say they do not want a particular worker. Staff should keep explaining care in a respectful way that fits the agreed plan and the person’s understanding. The objective is a necessary treatment decision made with the least avoidable restriction, not general concealment.

Support relatives and representatives with clear information about their role and the review process. A family member may have asked for covert administration because they fear the consequence of missed treatment. Explain the capacity and best-interests steps, the pharmacist’s role and the need to consider alternatives. Avoid promising that hidden medicine is a quick fix. If the resident has previously expressed wishes about the treatment, bring those into the decision even when the current conversation is difficult.

CQC Regulation 11 concerns consent and care or treatment for people who lack capacity. The provider should ensure its covert-medicine process sits within the Mental Capacity Act framework. NICE NG189 recognises unauthorised covert administration among potential safeguarding indicators. If staff discover hidden dosing outside an authorised plan, protect the resident, seek clinical advice and use the safeguarding and incident routes as appropriate.

Make the plan visible to the right people

A covert plan can fail if the prescriber knows about it but the night worker does not, or if the pharmacy changes a formulation without the care home being told. Create a controlled handover. The relevant staff should know which medicine is covered, the exact approved method, where the record is kept, what to do when a dose cannot be given and when review is due. Other people should not be given sensitive details without a need to know.

Keep the prescription, MAR, capacity assessment, best-interests record and pharmacist instruction consistent. A mismatch between these records is a safety issue. When a medicine is stopped or altered, update the covert plan and remove outdated instructions. If a resident returns from hospital, reconcile the new medicines list before using an old plan. A note that says “covert medicines authorised” is inadequate when the individual medicines have changed.

Train workers on the difference between a concealed medicine and a medicine given with food for swallowing support with the person’s knowledge. The latter may still need pharmaceutical advice, but it is not covert merely because food is involved. The decisive issue is whether the person knows they are receiving medicine. Workers should be able to explain the route for a new refusal and should know they cannot extend an authorised plan to another treatment on their own.

Protect records and privacy. Capacity and treatment information is sensitive. Store it in the approved care or medicines record with appropriate access. A general compliance platform might track that a policy review or staff competency is due, but should not receive detailed clinical notes by default. Give staff enough information to deliver care safely without exposing the resident’s treatment to unrelated roles.

Review the decision when circumstances change

NICE SC1 recommends regular review of whether covert administration is still needed. Set a review point in the plan and bring it forward if the resident’s capacity, health, medicine, formulation or behaviour changes. A resident who was delirious may later regain capacity. A medicine may be stopped, reduced or offered differently. A long-standing covert plan should not persist solely because the MAR repeats the instruction each month.

At review, ask whether the treatment achieved its aim, whether the resident had adverse effects, whether the administration method worked and whether alternatives are now available. Revisit the person’s wishes and any signs of distress. Confirm the prescriber and pharmacist still support the medicine and method. Record a decision to continue, change or stop covert administration for each medicine. A calendar reminder is only useful if it leads to a substantive review.

Audit delivered practice against the authorised plan. Was every dose prepared in the advised way? Were partial doses or rejected food recorded? Did workers ask for help when uncertain? Were new prescriptions mistakenly treated as covered? Check a sample of real administration events and talk to staff. A file containing a perfect best-interests form does not prove the resident received treatment safely or lawfully.

If a concern arises about unauthorised covert administration, separate immediate clinical assessment, safeguarding and organisational investigation. The resident may have received an altered formulation or an uncertain dose. Seek prescriber or pharmacist advice about clinical impact. Preserve the MAR and original records. Do not quietly add a backdated best-interests note to legitimise past action. The service should learn how the decision boundary failed and prevent recurrence.

A decision checklist before the first covert dose

• Has the resident refused this medicine, and have reasons and alternatives been explored?
• Has the prescribing professional assessed capacity for this treatment decision at this time?
• If capacity is lacking, has a medicine-specific best-interests process taken place?
• Were the resident’s wishes, family or advocate views and less restrictive options considered?
• Has the prescriber reviewed whether this medicine and dose remain necessary?
• Has a pharmacist confirmed the exact formulation and safe administration method?
• Are the prescription, MAR, care plan and best-interests record consistent?
• Do trained workers know what to do if the food or drink is not fully taken?
• Is there a named review date and an earlier trigger if capacity or treatment changes?

A “yes” on a form is not enough if the underlying assessment or advice is missing. If an urgent clinical situation arises before the process is complete, seek urgent professional advice about a lawful response. Do not improvise a hidden dose.

What Complys may support, subject to product review

Public Complys care pages describe staff competence, policies, audits and incident evidence. They do not verify a clinical covert-medicine authorisation workflow or integration with the MAR. A compliance task could remind a manager that a policy or competency review is due, but the legal and pharmaceutical decisions belong with the responsible professionals. Do not claim that Complys decides capacity, best interests, medicine suitability or safe crushing.

Suggested CTA: Ask Complys to demonstrate the current policy, competency and action-tracking features that could support medicines governance. Keep the resident’s detailed covert plan and MAR in approved clinical systems and have the product team confirm any integration claim.

Related tool opportunity: A medicine-specific decision and review checklist could prompt the team to record capacity, best interests, alternatives, prescriber and pharmacist advice, administration method and review trigger. It needs legal, clinical and pharmaceutical sign-off before release and must never authorise treatment by itself.